203 related articles for article (PubMed ID: 32860339)
1. Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision-making processes.
Long X; Wu L; Zeng X; Wu Z; Hu X; Jiang H; Lv Z; Yang C; Cai Y; Yang K; Li Y
Cancer Med; 2020 Oct; 9(20):7524-7536. PubMed ID: 32860339
[TBL] [Abstract][Full Text] [Related]
2. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
[TBL] [Abstract][Full Text] [Related]
3. Improving prostate biopsy decision making in Mexican patients: Still a major public health concern.
Amaya-Fragoso E; García-Pérez CM
Urol Oncol; 2021 Dec; 39(12):831.e11-831.e18. PubMed ID: 34193378
[TBL] [Abstract][Full Text] [Related]
4. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
[TBL] [Abstract][Full Text] [Related]
5. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
[TBL] [Abstract][Full Text] [Related]
6. Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies.
Van Neste L; Partin AW; Stewart GD; Epstein JI; Harrison DJ; Van Criekinge W
Prostate; 2016 Sep; 76(12):1078-87. PubMed ID: 27121847
[TBL] [Abstract][Full Text] [Related]
7. Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculator for Initial Prostate Biopsy by Incorporating the 2014 International Society of Urological Pathology Gleason Grading and Cribriform growth.
Roobol MJ; Verbeek JFM; van der Kwast T; Kümmerlin IP; Kweldam CF; van Leenders GJLH
Eur Urol; 2017 Jul; 72(1):45-51. PubMed ID: 28162815
[TBL] [Abstract][Full Text] [Related]
8. Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.
Hendriks RJ; van Oort IM; Schalken JA
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):12-19. PubMed ID: 27922627
[TBL] [Abstract][Full Text] [Related]
9. A Magnetic Resonance Imaging-Based Prediction Model for Prostate Biopsy Risk Stratification.
Mehralivand S; Shih JH; Rais-Bahrami S; Oto A; Bednarova S; Nix JW; Thomas JV; Gordetsky JB; Gaur S; Harmon SA; Siddiqui MM; Merino MJ; Parnes HL; Wood BJ; Pinto PA; Choyke PL; Turkbey B
JAMA Oncol; 2018 May; 4(5):678-685. PubMed ID: 29470570
[TBL] [Abstract][Full Text] [Related]
10. The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort.
Möller A; Olsson H; Grönberg H; Eklund M; Aly M; Nordström T
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):137-142. PubMed ID: 30171228
[TBL] [Abstract][Full Text] [Related]
11. The utility of PSA velocity in prediction of prostate cancer and high grade cancer after an initially negative prostate biopsy.
Elshafei A; Li YH; Hatem A; Moussa AS; Ethan V; Krishnan N; Li J; Jones JS
Prostate; 2013 Dec; 73(16):1796-802. PubMed ID: 24038200
[TBL] [Abstract][Full Text] [Related]
12. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
13. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report.
Klein EA; Chait A; Hafron JM; Kernen KM; Manickam K; Stephenson AJ; Wagner M; Zhu H; Kestranek A; Zaslavsky B; Stovsky M
Eur Urol; 2017 Dec; 72(6):942-949. PubMed ID: 28396176
[TBL] [Abstract][Full Text] [Related]
14. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.
Rubio-Briones J; Borque A; Esteban LM; Casanova J; Fernandez-Serra A; Rubio L; Casanova-Salas I; Sanz G; Domínguez-Escrig J; Collado A; Gómez-Ferrer A; Iborra I; Ramírez-Backhaus M; Martínez F; Calatrava A; Lopez-Guerrero JA
BMC Cancer; 2015 Sep; 15():633. PubMed ID: 26362197
[TBL] [Abstract][Full Text] [Related]
16. Artificial intelligence-aided detection for prostate cancer with multimodal routine health check-up data: an Asian multi-center study.
Song Z; Zhang W; Jiang Q; Deng L; Du L; Mou W; Lai Y; Zhang W; Yang Y; Lim J; Liu K; Park JY; Ng CF; Ong TA; Wei Q; Li L; Wei X; Chen M; Cao Z; Wang F; Chen R
Int J Surg; 2023 Dec; 109(12):3848-3860. PubMed ID: 37988414
[TBL] [Abstract][Full Text] [Related]
17. Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer.
Druskin SC; Tosoian JJ; Young A; Collica S; Srivastava A; Ghabili K; Macura KJ; Carter HB; Partin AW; Sokoll LJ; Ross AE; Pavlovich CP
BJU Int; 2018 Apr; 121(4):619-626. PubMed ID: 29232037
[TBL] [Abstract][Full Text] [Related]
18. Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone.
Niu XK; Li J; Das SK; Xiong Y; Yang CB; Peng T
BMC Med Imaging; 2017 Feb; 17(1):11. PubMed ID: 28143433
[TBL] [Abstract][Full Text] [Related]
19. Could Magnetic Resonance Imaging Help to Identify the Presence of Prostate Cancer Before Initial Biopsy? The Development of Nomogram Predicting the Outcomes of Prostate Biopsy in the Chinese Population.
Fang D; Zhao C; Ren D; Yu W; Wang R; Wang H; Li X; Yin W; Yu X; Yang K; Liu P; Shan G; Li S; He Q; Wang X; Xin Z; Zhou L
Ann Surg Oncol; 2016 Dec; 23(13):4284-4292. PubMed ID: 27464612
[TBL] [Abstract][Full Text] [Related]
20. Effect of pathologic revision and Ki67 and ERG immunohistochemistry on predicting radical prostatectomy outcome in men initially on active surveillance.
Bokhorst LP; Roobol MJ; Bangma CH; van Leenders GJ
Prostate; 2017 Jul; 77(10):1137-1143. PubMed ID: 28543353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
